Eric Souied Joins SeaBeLife - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Eric Souied Joins SeaBeLife

French biotechnology company, SeaBeLife, welcomes AMD specialist to its scientific committee

  • March 9, 2026

  • 2 min

Share

  • 1

    Professor Eric Souied has joined SeaBeLife's scientific committee to advance its dual-pathway strategy targeting retinal degeneration.

  • 2

    Souied will guide the company's ophthalmology program, focusing on inhibiting necroptosis and ferroptosis in retinal diseases.

  • 3

    SeaBeLife claims its platform uniquely addresses both necroptosis and ferroptosis mechanisms in tandem.

  • 4

    Souied has authored over 650 publications and identified the first genetic polymorphism linked to age-related macular degeneration.

  • 5

    SeaBeLife's lead candidate, SBL03, shows preclinical efficacy in geographic atrophy, affecting an estimated eight million people globally.

Original Source(s)

Eric Souied Joins SeaBeLife

  • March 9, 2026

Related Content

Highlights From Atlantic Coast Retina Club and Macula 2026

Renowned ophthalmologists gathered in Philadelphia to discuss groundbreaking strategies and cases at the Atlantic Coast Retina Club and Macula 2026 conference.

Vascular Alterations in the Choroid of Eyes Affected by Acute Macular Neuroretinopathy and Paracentral Acute Middle Maculopathy: Fresh Perspectives

GLP-1 Eye Effects Raise Questions

Authors describe both potential retinal benefits and possible rare optic nerve risks, while emphasizing that long-term ocular safety data remain limited as use expands.